Ph 1a/1b trial of OMX-040 in patients with advanced solid tumors advanced to expansion phase in kidney cancer and angiosarcoma
Apollon Papadimitriou, Ph.D., Chief Executive Officer of iOmx, concluded: “Kicking-off the Phase Ib segment of the OMX-0407 trial is a key development milestone for iOmx. The dose escalation data, including one long-lasting complete response in an indication of high medical need and additional signs of anti-tumor activity in other patients is very strong. We are confident that we are progressing towards providing a clinically meaningful, differentiated therapy for patients failing current cancer treatments and expect to report topline clinical proof-of-concept data by early 2026.”
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib